A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes
NCT01571648
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
5
Enrollment
INDUSTRY
Sponsor class
Conditions
Myelodysplastic Syndromes
Interventions
DRUG:
Oral azacitidine
Sponsor
Celgene